Pharmaceuticals

Personalized Medicine Drives Growth In Peptide And Oligonucleotide CDMO Market Is Supporting Development Across The Peptide And Oligonucleotide CDMO Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Peptide And Oligonucleotide CDMO Market Become By 2030 Compared To 2026?

The peptide and oligonucleotide CDMO market has experienced significant expansion in recent years. It is projected to grow from $2.42 billion in 2025 to $2.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. The growth observed in the past can be attributed to several factors including the increase in peptide-based therapeutics, the rising complexity of synthetic oligonucleotides, the limited in-house manufacturing capabilities of drug developers, the growing demands for regulatory compliance, and the early adoption of antisense and peptide drugs.

The peptide and oligonucleotide cdmo market size is anticipated to undergo significant growth over the coming years. It is projected to achieve a valuation of $4.03 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. This expansion during the forecast period is propelled by factors such as the broadening of oligonucleotide therapeutics pipelines, increased financial commitment to rare disease and oncology medications, an escalating requirement for expeditious clinical trial material manufacturing, an increasing inclination towards specialized CDMO alliances, and advancements in solid-phase synthesis techniques. Prominent developments expected in the forecast timeframe involve an uptick in the outsourcing of peptide and oligonucleotide production, a rising need for cGMP-compliant complex molecule manufacturing, the extension of comprehensive development and manufacturing services, an amplified emphasis on high-potency and high-purity therapeutics, and a greater embrace of scalable and adaptable manufacturing platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Growth Factors Are Strengthening The Peptide And Oligonucleotide CDMO Market Landscape?

The increasing acceptance of personalized medicine is anticipated to stimulate the expansion of the peptide and oligonucleotide CDMO markets in the coming period. Personalized medicine constitutes a healthcare methodology that customizes medical judgments and therapies to individual attributes, such as genetics, environment, and lifestyle. The rising uptake of personalized medicine is attributable to several elements, including breakthroughs in genomic technologies, enhanced comprehension of disease mechanisms at the molecular level, and the demand for more efficacious and targeted treatment options specifically adapted to individual patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a vital function in personalized medicine by manufacturing bespoke therapeutic peptides and oligonucleotides designed for specific patient requirements. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the expanding adoption of personalized medicine is propelling the growth of the peptide and oligonucleotide CDMO market.

What Segment Categories Are Evaluated In The Peptide And Oligonucleotide CDMO Market Study?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Trends Are Influencing The Future Of The Peptide And Oligonucleotide CDMO Market?

Leading companies operating within the peptide and oligonucleotide CDMO market are concentrating on forging strategic alliances to bolster their service offerings, expand their technological capabilities, and enhance their market penetration. Peptide development and production partnerships involve collaborative agreements between two organizations focused on advancing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), established a partnership with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance aims to utilize PolyPeptide’s cGMP manufacturing capacities and market access, combined with Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is dedicated to jointly exploring the development of suitable peptide candidates with the objective of achieving more sustainable production of peptide-based APIs.

Who Are The Businesses Driving Activity In The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Peptide And Oligonucleotide CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regional Market Leads The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peptide And Oligonucleotide CDMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795